AML-643 Precision-Engineered Cell Therapy Orca-T Demonstrates High Relapse-Free Survival at 1 Year While Reducing Graft-Versus-Host Disease (GvHD) and Toxicity
Published in: | Clinical Lymphoma Myeloma and Leukemia |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Elsevier BV
2023
|
Subjects: | |
Online Access: | http://dx.doi.org/10.1016/s2152-2650(23)01089-3 https://api.elsevier.com/content/article/PII:S2152265023010893?httpAccept=text/xml https://api.elsevier.com/content/article/PII:S2152265023010893?httpAccept=text/plain |
Description not available. |